Publications

Publication of research results is a pivotal requirement for a comprehensive improvement of treatment concepts. iOMEDICO supports the international guidelines for transparency and reporting of medical research results.

We regularly present our data at national and international conferences. Our publications are published in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and scientists of iOMEDICO.

TITEL
STUDIE
JAHR
Bendamustine versus chlorambucil as first-line treatment in B cell chronic lymphocytic leukemia: An updated analysis from an international phase III study.

Knauf, W.U., Lissitchkov, T., Aldaoud, A., Liberati, A., Loscertales, J., Herbrecht, R., Juliusson, G., Postner, G., Gercheva, L., Goranov, S., Becker, M., Hoeffken, K., Huguet, F., Foa, R., Merkle, K., Montillo, M., 2008.

Blood 112(11), 2091.

Abstract

Indikation: Hämoblastosen / Veranstaltung: ASH / Journal: Blood
02 CLL III
2008
Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausalearly breast cancer.

Jones, S.E., Seynaeve, C., Hasenburg, A., Rea, D., Vannetzel, J.M., Paridaens, R., Markopoulos, C., Hozumi, Y., Putter, H., Hille, E., Kieback, D.G., Asmar, L., Smeets, J., Urbanski, R., Bartlett, J., van de Velde and D Rea, C., 2008.

Cancer Res 69(2 Supplement), 15. doi:10.1158/0008-5472.SABCS-15

Abstract

Indikation: Mammakarzinom / Veranstaltung: SABCS / Journal: Cancer Research
TEAM
2008
Bone Effects of Exemestane vs. Tamoxifen within the German TEAM trial: Results of a Prospective Randomized Bone Sub-Study.

Hadji, P., Ziller, M., Kieback, D., Dornoff, W., Tessen, H., Kuck, J., Hasenburg, A., 2008.

Cancer Res 69(2 Supplement), 1143. doi:10.1158/0008-5472.SABCS-1143

Abstract

Indikation: Mammakarzinom / Veranstaltung: SABCS / Journal: Cancer Research
TEAM
2008
Colon Registry: Influence of comorbidity on the choice of chemotherapeutic treatment. A joint project of the AIO and the AKS.

Freier, W., Arnold, D., Otremba, B., Marschner, N., 2008.

Onkologie 31 (suppl 4)(P301), 109. doi:10.1159/000161574

Abstract

Download

Indikation: Kolorektalkarzinom / Veranstaltung: DGHO / Journal: Onkologie
TKK
2008
A prospective planned pathology study within the TEAM trial confirms that progesterone receptor expression is prognostic but not predictive for differential response to exemestane versus tamoxifen.

Bartlett, J., Brookes, C., Billingham, L., Campell, F., Gnant, M., Hasenburg, A., Hille, E., Kay, C., Kieback, D., Markopoulos, C., Meershok-Klein Kranenberg, E., Mallon, E., Paridaens, R., Putter, H., Robson, T., Seynaeve, C., van de Velde and D Rea, C., 2008.

Cancer Res 69 (2 Supplement), 81. doi:10.1158/0008-5472.SABCS-81

Abstract

Indikation: Mammakarzinom / Veranstaltung: SABCS / Journal: Cancer Research
TEAM
2008
Bendamustine versus chlorambucil in treatment-naive patients with B-cell chronic lymphocytic leukemia (B-CLL): Results of an international phase III study.

Knauf, W.U., Lissichkov, T., Aldaoud, A., Herbrecht, R., Liberati, A.M., Loscertales, J., Juliusson, G., Dittrich, C., Merkle, K., 2007.

Blood 110(11), 2043.

Abstract

Indikation: Hämoblastosen / Veranstaltung: ASH / Journal: Blood
02 CLL III
2007
Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.

Twelves, C.J., 2006.

Clin Colorectal Cancer 6, 278–287.

Abstract

Indikation: Kolorektalkarzinom / Veranstaltung: - / Journal: Clinical Colorectal Cancer
X-ACT
2006
Capecitabine as adjuvant treatment for stage III colon cancer.

Twelves, C., Wong, A., Nowacki, M.P., Abt, M., Burris, H., Carrato, A., Cassidy, J., Cervantes, A., Fagerberg, J., Georgoulias, V., Husseini, F., Jodrell, D., Koralewski, P., Kröning, H., Maroun, J., Marschner, N., McKendrick, J., Pawlicki, M., Rosso, R., Schüller, J., Seitz, J.-F., Stabuc, B., Tujakowski, J., Van Hazel, G., Zaluski, J., Scheithauer, W., 2005.

N Engl J Med 352, 2696–704. doi:10.1056/NEJMoa043116

Abstract

Indikation: Kolorektalkarzinom / Veranstaltung: - / Journal: New England Journal of Medicine
X-ACT
2005
Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer.

Karthaus, M., Ballo, H., Abenhardt, W., Steinmetz, T., Geer, T., Schimke, J., Braumann, D., Behrens, R., Behringer, D., Kindler, M., Messmann, H., Boeck, H.-P., Greinwald, R., Kleeberg, U., 2005.

Oncology 68, 326–32. doi:10.1159/000086971

Abstract

Indikation: Kolorektalkarzinom / Veranstaltung: - / Journal: Oncology
BUC-37/CID
2005
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.

Scheithauer, W., McKendrick, J., Begbie, S., Borner, M., Burns, W.I., Burris, H.A., Cassidy, J., Jodrell, D., Koralewski, P., Levine, E.L., Marschner, N., Maroun, J., Garcia-Alfonso, P., Tujakowski, J., Van Hazel, G., Wong, A., Zaluski, J., Twelves, C., 2003.

Ann. Oncol. 14, 1735–1743.

Abstract

Indikation: Kolorektalkarzinom / Veranstaltung: - / Journal: Annals of Oncology
X-ACT
2003